Press release – For immediate release – 8:00 am CEST
Median Technologies’ Global iCRO Team to participate in the 2023 ESMO Congress, Oct 20 – 24, 2023, Madrid, Spain
- The iCRO team will be available at Booth #552, Exhibition Hall 5 during the entire industry exhibition duration.
- Members of the Median Technologies’ team across the globe, including China, United States, and Europe, will be in attendance.
- Median’s iCRO business provides best-in-class central imaging services for oncology clinical trials.
Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take place in Madrid, Spain (venue: IFEMA).
The event, scheduled from October 20th to 24th, promises to be a remarkable platform for the exchange of groundbreaking insights and cutting-edge developments in the field of oncology.
“As a testament to the commitment of advancing cancer care worldwide, we will be participating with the goal of sharing our expertise in clinical trial imaging as well as advanced, AI-powered insights,” said Nicolas Dano, Chief Operating Officer, iCRO, of Median Technologies. “We are thrilled to be bringing together for the first time our expert teams spanning across the Europe, United States, and China, and invite all attendees to visit booth #552 to engage with our experts and experience firsthand the impact of our pioneering solutions.”
More about the ESMO congress: https://www.esmo.org/meeting-calendar/esmo-congress-2023
Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit